Short answer: recruitment is the single biggest cause of trial delay, and unreadable participant documents make it worse. Around 80% of trials fail to meet their initial enrolment target and timeline, at a cost of up to US $8 million per day in lost revenue [1]. Readability is one of the few enrolment variables a sponsor can change in weeks rather than quarters.<\/p>\n
![\"\"](\"https:\/\/lifesciences.enago.com\/blogs\/wp-content\/uploads\/2026\/08\/els-1.png\")
Figure 1. The cost of unclear participant communication. Bracketed numerals correspond to the reference list.<\/em><\/h6>\nThe spending pattern is easy to check. The global eClinical technology market is forecast at US $15.80 billion in 2026 [2]. In the HHS-commissioned cost analysis that still anchors most trial budget benchmarks, patient recruitment accounts for 1.7% to 2.7% of a trial’s total cost, depending on phase, and patient retention for 0.2% to 0.3% [3]. Clinical procedures take 15% to 22%. Administrative staff take 11% to 29% [3].<\/p>\n
So everything used to find participants, explain the study to them, and keep them enrolled sits at roughly one-fortieth of a trial’s budget, against a delay cost of up to $8 million a day.<\/p>\n
Sponsors have answered the recruitment problem with decentralized trials, digital recruitment platforms, and AI-powered patient matching. None of it answers what a prospective participant is actually asking: What am I signing up for? Can I trust this process? Will someone answer my questions after I enroll?<\/em><\/p>\nSponsors measure recruitment as a single milestone. Participants experience a continuous relationship \u2014 awareness, consent, adherence, retention \u2014 connected by communication. CISCRP’s 2025 Perceptions & Insights study, a global survey of more than 12,800 patients and members of the public, found that 88% consider regular study updates somewhat or very important to their participation experience. In the same survey, 42% of participants reported receiving any results after completing a study, and 58% received none. Among those who did receive a summary of overall results, 94% found it somewhat or very helpful [4].<\/p>\n
![\"\"](\"https:\/\/lifesciences.enago.com\/blogs\/wp-content\/uploads\/2026\/08\/els-2.png\")
<\/p>\n
Figure 2. Sponsors measure a milestone; participants experience a relationship.<\/em><\/h6>\nFor years, the case for plain language rested on ethics. In 2024 it acquired a price tag. A retrospective analysis in eClinicalMedicine<\/em> examined consent forms from 798 federally funded trials, found a mean Flesch-Kincaid reading level of grade 12, and then linked readability to outcomes: each additional grade level of reading difficulty was associated with a 16% higher dropout rate<\/a> (IRR 1.16; 95% CI 1.12\u20131.22) [5].<\/p>\nNot comprehension scores. Not satisfaction surveys. Dropout.<\/p>\n
That is the point at which participant communication stops being a support function. A consent form written in dense regulatory prose can suppress enrollment before a study opens, and a plain-language rewrite<\/a> costs a fraction of one day of trial delay.<\/p>\nHow Patient-Centered Communication Improves Clinical Trial Outcomes<\/strong><\/h3>\n![\"\"](\"https:\/\/lifesciences.enago.com\/blogs\/wp-content\/uploads\/2026\/08\/els-3.png\")
<\/p>\n
Figure 3. Three trials, three lessons in participant communication.<\/em><\/h6>\n\nThe NIH’s All of Us<\/em> program built recruitment on trust: plain-language materials, translation, and community partners rather than channels. In its June 2026 data release<\/a>, more than 645,000 of the 747,000 participants in the dataset, 86% came from communities historically underrepresented in biomedical research, and the program had returned more than 733,000 personalized DNA results to over 277,000 participants [6]. That is a writing and translation achievement, executed at scale.<\/p>\n<\/blockquote>\nThe VOICE HIV-prevention trial shows the inverse. Retention exceeded 90% and participants reported taking the study product; plasma and swab testing put actual adherence near 34% [7]. Later interviews with 171 former participants found women who feared stigma at home, or who didn’t want to disappoint staff who had been kind to them [8]. The failure was the absence of a safe channel in which to say I stopped<\/em>.<\/p><\/blockquote>\nRECOVERY went the other way: one primary outcome, online randomisation, and a two-page patient information sheet [9]. It recruited more than 47,000 participants across six countries and identified four effective COVID-19 treatments [10].<\/p><\/blockquote>\n
Regulation Has Caught Up With Participant Communication<\/strong><\/h3>\nParticipant-facing documents are no longer a matter of goodwill. They are regulated deliverables with named owners, review cycles, and dates.<\/p>\n
![\"\"](\"https:\/\/lifesciences.enago.com\/blogs\/wp-content\/uploads\/2026\/08\/els-4.png\")
<\/p>\n
Figure 4. ICH E6(R3) effective dates by jurisdiction, with the adjacent lay summary and consent requirements.<\/em><\/h6>\nICH E6(R3) rebuilt Good Clinical Practice around participant-centricity and requires consent processes that are clear and comprehensible [11]. The overarching principles and Annex 1 became effective in the EU on 23 July 2025 [12]. FDA published the final guidance on 9 September 2025, though it has not set a formal US compliance date [13]. Health Canada’s adoption became effective on 1 April 2026, with a six-month implementation window closing 30 September 2026 and full compliance expected from 1 October 2026 [14]. Annex 2, covering non-traditional interventional trials, comes into effect in the EU on 15 January 2027 [12].<\/p>\n
Two adjacent requirements point the same way. EU CTR Article 37 requires a lay summary of trial results for every trial, whatever the outcome [15]. FDA’s informed consent guidance explicitly encourages diagrams and video [16].<\/p>\n
Read together, these are not compliance line items to be closed out. They change who owns the consent form, the participant information sheet, and the lay summary, and when those documents enter a study plan. If they are still being drafted in the weeks before first patient in, there is no room left for user testing with patients, and no room for clinical trial translation<\/a> into every participating country’s language.<\/p>\n
Sponsors measure recruitment as a single milestone. Participants experience a continuous relationship \u2014 awareness, consent, adherence, retention \u2014 connected by communication. CISCRP’s 2025 Perceptions & Insights study, a global survey of more than 12,800 patients and members of the public, found that 88% consider regular study updates somewhat or very important to their participation experience. In the same survey, 42% of participants reported receiving any results after completing a study, and 58% received none. Among those who did receive a summary of overall results, 94% found it somewhat or very helpful [4].<\/p>\n
<\/p>\n
Figure 2. Sponsors measure a milestone; participants experience a relationship.<\/em><\/h6>\nFor years, the case for plain language rested on ethics. In 2024 it acquired a price tag. A retrospective analysis in eClinicalMedicine<\/em> examined consent forms from 798 federally funded trials, found a mean Flesch-Kincaid reading level of grade 12, and then linked readability to outcomes: each additional grade level of reading difficulty was associated with a 16% higher dropout rate<\/a> (IRR 1.16; 95% CI 1.12\u20131.22) [5].<\/p>\nNot comprehension scores. Not satisfaction surveys. Dropout.<\/p>\n
That is the point at which participant communication stops being a support function. A consent form written in dense regulatory prose can suppress enrollment before a study opens, and a plain-language rewrite<\/a> costs a fraction of one day of trial delay.<\/p>\nHow Patient-Centered Communication Improves Clinical Trial Outcomes<\/strong><\/h3>\n<\/p>\n
Figure 3. Three trials, three lessons in participant communication.<\/em><\/h6>\n\nThe NIH’s All of Us<\/em> program built recruitment on trust: plain-language materials, translation, and community partners rather than channels. In its June 2026 data release<\/a>, more than 645,000 of the 747,000 participants in the dataset, 86% came from communities historically underrepresented in biomedical research, and the program had returned more than 733,000 personalized DNA results to over 277,000 participants [6]. That is a writing and translation achievement, executed at scale.<\/p>\n<\/blockquote>\nThe VOICE HIV-prevention trial shows the inverse. Retention exceeded 90% and participants reported taking the study product; plasma and swab testing put actual adherence near 34% [7]. Later interviews with 171 former participants found women who feared stigma at home, or who didn’t want to disappoint staff who had been kind to them [8]. The failure was the absence of a safe channel in which to say I stopped<\/em>.<\/p><\/blockquote>\nRECOVERY went the other way: one primary outcome, online randomisation, and a two-page patient information sheet [9]. It recruited more than 47,000 participants across six countries and identified four effective COVID-19 treatments [10].<\/p><\/blockquote>\n
Regulation Has Caught Up With Participant Communication<\/strong><\/h3>\nParticipant-facing documents are no longer a matter of goodwill. They are regulated deliverables with named owners, review cycles, and dates.<\/p>\n
<\/p>\n
Figure 4. ICH E6(R3) effective dates by jurisdiction, with the adjacent lay summary and consent requirements.<\/em><\/h6>\nICH E6(R3) rebuilt Good Clinical Practice around participant-centricity and requires consent processes that are clear and comprehensible [11]. The overarching principles and Annex 1 became effective in the EU on 23 July 2025 [12]. FDA published the final guidance on 9 September 2025, though it has not set a formal US compliance date [13]. Health Canada’s adoption became effective on 1 April 2026, with a six-month implementation window closing 30 September 2026 and full compliance expected from 1 October 2026 [14]. Annex 2, covering non-traditional interventional trials, comes into effect in the EU on 15 January 2027 [12].<\/p>\n
Two adjacent requirements point the same way. EU CTR Article 37 requires a lay summary of trial results for every trial, whatever the outcome [15]. FDA’s informed consent guidance explicitly encourages diagrams and video [16].<\/p>\n
Read together, these are not compliance line items to be closed out. They change who owns the consent form, the participant information sheet, and the lay summary, and when those documents enter a study plan. If they are still being drafted in the weeks before first patient in, there is no room left for user testing with patients, and no room for clinical trial translation<\/a> into every participating country’s language.<\/p>\n
Not comprehension scores. Not satisfaction surveys. Dropout.<\/p>\n
That is the point at which participant communication stops being a support function. A consent form written in dense regulatory prose can suppress enrollment before a study opens, and a plain-language rewrite<\/a> costs a fraction of one day of trial delay.<\/p>\n The NIH’s All of Us<\/em> program built recruitment on trust: plain-language materials, translation, and community partners rather than channels. In its June 2026 data release<\/a>, more than 645,000 of the 747,000 participants in the dataset, 86% came from communities historically underrepresented in biomedical research, and the program had returned more than 733,000 personalized DNA results to over 277,000 participants [6]. That is a writing and translation achievement, executed at scale.<\/p>\n<\/blockquote>\n The VOICE HIV-prevention trial shows the inverse. Retention exceeded 90% and participants reported taking the study product; plasma and swab testing put actual adherence near 34% [7]. Later interviews with 171 former participants found women who feared stigma at home, or who didn’t want to disappoint staff who had been kind to them [8]. The failure was the absence of a safe channel in which to say I stopped<\/em>.<\/p><\/blockquote>\n RECOVERY went the other way: one primary outcome, online randomisation, and a two-page patient information sheet [9]. It recruited more than 47,000 participants across six countries and identified four effective COVID-19 treatments [10].<\/p><\/blockquote>\n Participant-facing documents are no longer a matter of goodwill. They are regulated deliverables with named owners, review cycles, and dates.<\/p>\n ICH E6(R3) rebuilt Good Clinical Practice around participant-centricity and requires consent processes that are clear and comprehensible [11]. The overarching principles and Annex 1 became effective in the EU on 23 July 2025 [12]. FDA published the final guidance on 9 September 2025, though it has not set a formal US compliance date [13]. Health Canada’s adoption became effective on 1 April 2026, with a six-month implementation window closing 30 September 2026 and full compliance expected from 1 October 2026 [14]. Annex 2, covering non-traditional interventional trials, comes into effect in the EU on 15 January 2027 [12].<\/p>\n Two adjacent requirements point the same way. EU CTR Article 37 requires a lay summary of trial results for every trial, whatever the outcome [15]. FDA’s informed consent guidance explicitly encourages diagrams and video [16].<\/p>\n Read together, these are not compliance line items to be closed out. They change who owns the consent form, the participant information sheet, and the lay summary, and when those documents enter a study plan. If they are still being drafted in the weeks before first patient in, there is no room left for user testing with patients, and no room for clinical trial translation<\/a> into every participating country’s language.<\/p>\nHow Patient-Centered Communication Improves Clinical Trial Outcomes<\/strong><\/h3>\n
<\/p>\nFigure 3. Three trials, three lessons in participant communication.<\/em><\/h6>\n
\n
Regulation Has Caught Up With Participant Communication<\/strong><\/h3>\n
<\/p>\nFigure 4. ICH E6(R3) effective dates by jurisdiction, with the adjacent lay summary and consent requirements.<\/em><\/h6>\n
![\"\"](\"https:\/\/lifesciences.enago.com\/blogs\/wp-content\/uploads\/2025\/02\/Rebecca_profile-img-1-e1739861336154-150x150.jpg\")
<\/p>\n